Allopurinol Powder CAS 315-30-0

Route 1:

Starting from ethyl cyanoacetate (2), it is condensed with triethyl orthoformate in acetic anhydride to obtain 3. It is then cyclized with hydrazine to form 3-amino-4-ethyloxazole methyl formate (4). Finally, 1 is prepared in formamide with a total yield of 41%.

The specific reaction conditions and mechanism of this step may vary depending on the literature, as there are multiple methods for synthesizing allopurinol. But usually, this step involves further conversion of 3-amino-4-ethyloxazolecarboxylic acid methyl ester, which may include oxidation, rearrangement, hydrolysis, and other steps.
Description: In formamide, 3-amino-4-ethyloxazolecarboxylic acid methyl ester may undergo a series of transformations, including possible ring opening, functional group transformation (such as nitrile conversion to amide or carboxyl group), cyclization, and other steps, ultimately forming allopurinol. The exact mechanism and conditions of these steps need to refer to specific literature or patents.

Note: As the synthesis of allopurinol is a complex process and may involve multiple patented technical details, the description of the third step above is highly conceptual. In actual synthesis, it is necessary to consult relevant literature in detail to obtain accurate information. Finally, it should be emphasized that the overall yield of the entire synthesis route is 41%, which means that there will be some loss of raw materials and generation of by-products in each step of the reaction. Therefore, when designing and optimizing the synthesis route, it is necessary to carefully consider the reaction conditions and product purification methods at each step to improve the overall yield.

Route 2:

Starting from malononitrile (5), it is condensed with triethyl orthoformate in acetic anhydride to obtain 6. Water and hydrazine are added to obtain 3-amino-4-pyrazole (7), which is then hydrolyzed with sulfuric acid to synthesize the intermediate 3-amino-4-pyrazole formamide half sulfate (8). Finally, allopurinol is obtained in formamide.

Reaction conditions: concentrated sulfuric acid, heating. Reaction equation: 3-amino-4-pyrazolecarboxylic acid ethyl ester+concentrated sulfuric acid ⟶ 3-amino-4-pyrazolecarboxylic acid ⋅ H2SO4 (semi sulfate form)
In this step, the ester group undergoes hydrolysis under the action of concentrated sulfuric acid, generating carboxyl groups. Due to the strong acidity of sulfuric acid, the product may exist in the form of semi sulfate.

Reaction conditions: formamide, heating, catalyst may also be required. Reaction equation (schematic, as the specific mechanism may be complex): 3-amino-4-pyrazolecarboxylic acid ⋅ H2SO4+formamide allopurinol+byproduct
This step is the final and most complex step of the synthesis route. Here, the bisulfate of 3-amino-4-pyrazolecarboxamide undergoes some kind of cyclization reaction in the formamide, producing allopurinol.

Distribution

The distribution characteristics of allopurinol in the body mainly depend on its physical and chemical properties and its ability to bind to plasma proteins. However, it is worth noting that allopurinol and its active metabolite oxypurinol cannot bind to plasma proteins, which means that their free concentration in the blood is high and can quickly distribute to various tissues and organs throughout the body.
When allopurinol is orally administered to the human body, it is rapidly absorbed in the gastrointestinal tract and reaches its peak blood concentration within 2 to 6 hours after administration. Due to being unaffected by plasma protein binding, allopurinol can freely penetrate the cell membrane and enter the interior of tissue cells. This enables it to exert a direct uric acid lowering effect in gout lesions such as joints, kidneys, etc.
In addition, allopurinol has a longer residence time in tissues, which helps to continuously inhibit the production of uric acid and reduce the deposition of uric acid crystals. Especially in the chronic phase of gout, allopurinol can stably maintain low plasma uric acid levels, promote the dissolution of gouty tophi, and repair joint tissue.

Metabolize

The metabolic process of allopurinol in the body mainly occurs in the liver. In the liver, allopurinol is converted into active metabolites such as oxypurinol through a series of enzymatic reactions. These metabolites have pharmacological effects similar to allopurinol, which can further inhibit the activity of xanthine oxidase and reduce the production of uric acid.
It is worth noting that the metabolic process of allopurinol is influenced by multiple factors. For example, patients with liver dysfunction may have reduced metabolic capacity for allopurinol, leading to prolonged drug retention time and increased side effects in the body. In addition, certain drugs such as rifampicin and azathioprine may interact with allopurinol, affecting its metabolic rate and efficacy.

Excretion

The excretion of allopurinol and its metabolites in the body is mainly carried out through the kidneys. They are excreted in the form of their original form or metabolites with urine. Renal excretion is the main pathway for the elimination of allopurinol, therefore the state of renal function has a significant impact on the rate and effectiveness of allopurinol excretion.
Under normal circumstances, the half-life of allopurinol is 14-28 hours. This means that during a period of time after administration, the drug concentration will gradually decrease and eventually be completely eliminated. However, in cases of renal insufficiency, the excretion rate of allopurinol slows down, leading to prolonged drug retention time in the body and increased plasma concentration. This may increase the risk of drug side effects and affect treatment efficacy. In addition, the use of uric acid excretory drugs such as benzbromarone can promote the excretion rate of allopurinol and its metabolites. However, when using combination therapy, attention should be paid to the interactions between drugs and the potential risk of side effects. The distribution, metabolism, and excretion process in the body is a complex and precise process. By understanding its pharmacokinetic properties and tailoring personalized treatment plans based on the patient's specific situation, the therapeutic effect of allopurinol can be maximized while reducing the occurrence of adverse reactions.